Klivira
Request demo

Streamlining Enhertu Prior Authorization for Dermatology

Managing Enhertu prior authorization for dermatology practices requires navigating complex payer policies and clinical documentation. Klivira's platform automates this process, ensuring faster approvals and reduced administrative burden.

Revenue cycle directors and prior authorization coordinators in dermatology face unique challenges, from managing high volumes of biologic PAs to ensuring compliance with evolving clinical guidelines. While Enhertu is a high-volume PA target across various specialties, its authorization process, like other specialty drugs, benefits from an automated approach that integrates seamlessly with existing dermatological workflows. Klivira provides a robust solution designed to address these specific needs.

The Landscape of Prior Authorization in Dermatology

Dermatology practices frequently manage prior authorizations for high-cost biologics, specialty topicals, and complex procedures like Mohs surgery. This necessitates deep understanding of payer-specific criteria, step therapy requirements, and clinical guideline adherence. An efficient system is crucial for maintaining patient access and optimizing revenue cycles.

Common Prior Authorization Triggers in Dermatology

  • Biologics for psoriasis, psoriatic arthritis, and atopic dermatitis (e.g., TNF inhibitors, IL-17/23 inhibitors, JAK inhibitors).
  • Biologics for hidradenitis suppurativa.
  • Mohs micrographic surgery for non-melanoma skin cancers.
  • Advanced skin cancer treatments, including immunotherapies and targeted therapies.
  • Self-administered home phototherapy.
  • Specific biopsy and excision codes beyond routine procedures.

Navigating Enhertu's PA within Dermatology Workflows

Enhertu, like many specialty drugs, is a frequent target for prior authorization across diverse payer types, including commercial, Medicare Advantage, and Medicaid managed care plans. While its primary indications are outside typical dermatological practice, if prescribed within a dermatology setting for an approved use, the PA process must align with the specialty's general documentation and submission protocols. Klivira's platform is built to adapt to these varied requirements, ensuring comprehensive PA management.

Essential Documentation for Dermatology Prior Authorizations

  • Diagnosis and severity scores (e.g., PASI, BSA for psoriasis; EASI, SCORAD for atopic dermatitis).
  • Documentation of prior topical therapy trials.
  • Evidence of prior conventional systemic therapy trials (e.g., methotrexate, cyclosporine).
  • TB and hepatitis screening results pre-biologic initiation.
  • Adherence to AAD Clinical Guidelines and NCCN guidelines for skin cancers.
  • Conformance with Mohs Appropriate Use Criteria (AUC) regarding site and tumor type.

Mitigating Common Prior Authorization Denials

Dermatology practices frequently encounter denials due to issues such as non-compliance with step therapy protocols, insufficient documentation of disease severity, or discrepancies with Mohs AUC. Proactive identification of these common pitfalls, supported by an automated system that flags missing information and guides staff through payer-specific requirements, is key to improving approval rates.

Klivira's Automated Approach to Dermatology Prior Authorizations

  • AAD-guideline-aware step-therapy logic for biologics.
  • Automated AUC validation for Mohs surgery.
  • Streamlined periodic re-authorization workflows for chronic treatments.
  • Intelligent routing for medical-vs-pharmacy benefit claims.
  • Integration with EMRs for efficient data extraction and submission.
  • Real-time status tracking across diverse payer portals and channels.

Frequently asked questions

How does Klivira handle periodic re-authorization for dermatology biologics?

Klivira automates the tracking and submission of periodic re-authorizations, which are common for chronic biologic treatments in dermatology, typically on 6 or 12-month cycles. The system proactively alerts staff to upcoming re-authorization needs and pre-populates forms with recurring patient data.

Can Klivira integrate with our EMR to pull patient data for dermatology PAs?

Yes, Klivira integrates with major EMR systems using standards like SMART on FHIR. This allows for seamless extraction of relevant patient demographics, diagnoses, lab results, and treatment histories, significantly reducing manual data entry for dermatology prior authorizations.

Does Klivira support Mohs surgery prior authorization requirements?

Absolutely. Klivira incorporates logic for Mohs Appropriate Use Criteria (AUC) validation, helping practices ensure that documentation for site, tumor type, and prior treatments aligns with payer policies, thereby reducing denials for Mohs micrographic surgery.

How does Klivira address step therapy requirements for psoriasis or atopic dermatitis biologics?

Klivira's platform is designed with AAD-guideline-aware step-therapy logic. It guides PA coordinators to document trials of prior topical therapies, phototherapy, and conventional systemic agents, ensuring all necessary steps are completed before submitting for biologic approval.

What if Enhertu is prescribed under a medical benefit versus a pharmacy benefit?

Klivira’s platform intelligently routes prior authorization requests based on whether the drug falls under the medical or pharmacy benefit. This ensures that Enhertu, or any other specialty drug, is submitted through the correct channel (e.g., X12 278, NCPDP SCRIPT) to the appropriate payer.

Related coverage

Other enhertu prior authorization by payer

Other enhertu prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo